Analyst Reco. EyePoint Pharmaceuticals, Inc.

Equities

EYPT

US30233G2093

Market Closed - Nasdaq Other stock markets 01:30:00 22/06/2024 am IST			5-day change	1st Jan Change
8.47 ^USD	+3.80%		-9.70%	-63.35%

12/06	Transcript : EyePoint Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 03:20 PM
04/06	JPMorgan Adjusts EyePoint Pharmaceuticals Price Target to $32 From $35, Maintains Overweight Rating	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

JPMorgan Adjusts EyePoint Pharmaceuticals Price Target to $32 From $35, Maintains Overweight Rating	04/06	MT
Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating	08/05	MT
Chardan Research Adjusts EyePoint Pharmaceuticals' PT to $28 From $39 After Data From PAVIA Study of Duravyu Disappoint; Keeps Buy Rating	07/05	MT
Mizuho Securities Cuts Price Target on EyePoint Pharmaceuticals to $30 From $39, Maintains Buy Rating	07/05	MT
Mizuho Boosts PT on EyePoint Pharmaceuticals to $39 From $30 Ahead of Q4 2023 Earnings Announcement, Keeps Buy Rating	15/02	MT
JPMorgan Starts EyePoint Pharmaceuticals With Overweight Rating, $35 Price Target	22/01	MT
Capital One Starts Coverage on EyePoint Pharmaceuticals with Overweight Rating, $44 Price Target	11/12	MT
Mizuho Ups Price Target on EyePoint Pharmaceuticals to $30 From $20, Citing 'Resoundingly Positive' Data for Lead Asset EYP-1901, Reiterates Buy Rating	07/12	MT
HC Wainwright Adjusts Price Target on EyePoint Pharmaceuticals to $25 From $27, Keeps Buy Rating	02/11	MT
Mizuho Initiates EyePoint Pharmaceuticals With Buy Rating, Price Target is $20	02/11	MT
JonesTrading Initiates EyePoint Pharmaceuticals at Buy With $26 Price Target	14/23/14	MT
HC Wainwright Adjusts Price Target on EyePoint Pharmaceuticals to $27 From $25, Keeps Buy Rating	19/23/19	MT
Chardan Raises Price Target on EyePoint Pharmaceuticals to $22 From $21, Keeps Buy Rating	19/23/19	MT
Guggenheim Adjusts Price Target on EyePoint Pharmaceuticals to $52 From $60, Maintains Buy Rating	11/22/11	MT
HC Wainwright Lifts Price Target on EyePoint Pharmaceuticals to $25 From $24, Reiterates Buy Rating	04/22/04	MT
Chardan Capital Initiates EyePoint Pharmaceuticals at Buy with $21 Price Target	07/22/07	MT
Guggenheim Adjusts Price Target on EyePoint Pharmaceuticals to $75 From $22, Maintains Buy Rating	15/21/15	MT
Cowen Adjusts Price Target on EyePoint Pharmaceuticals to $35 From $25, Keeps Outperform Rating	15/21/15	MT
HC Wainwright Adjusts Price Target on EyePoint Pharmaceuticals to $24 From $15, Keeps Buy Rating	15/21/15	MT
EYEPOINT PHARMACEUTICALS : HC Wainwright Adjusts EyePoint Pharmaceuticals' Price Target to $15 From $16, Maintains Buy Rating	06/21/06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. EyePoint Pharmaceuticals, Inc.

Equities

EYPT

US30233G2093

Analyst Reco.

Filters